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Knowledge on the molecular mechanisms underlying metastasis colonization in Non-Small Cell Lung 
Cancer (NSCLC) remains incomplete. A complete overview integrating driver mutations, primary 
tumour heterogeneity and overt metastasis lacks the dynamic contribution of disseminating metastatic 
cells due to the inaccessibility to the molecular profiling of Circulating Tumour Cells (CTCs). By 
combining immunoisolation and whole genome amplification, we performed a global gene expression 
analysis of EpCAM positive CTCs from advanced NSCLC patients. We identified an EpCAM+ CTC-specific 
expression profile in NSCLC patients mostly associated with cellular movement, cell adhesion and cell-
to-cell signalling mediated by PI3K/AKT, ERK1/2 and NF-kB pathways. NOTCH1 emerged as a driver 
connecting active signalling pathways, with a reduced number of related candidate genes (NOTCH1, 
PTP4A3, LGALS3 and ITGB3) being further validated by RT-qPCR on an independent cohort of NSCLC 
patients. In addition, these markers demonstrated high prognostic value for Progression-Free Survival 
(PFS). In conclusion, molecular characterization of EpCAM+ CTCs from advanced NSCLC patients 
provided with highly specific biomarkers with potential applicability as a “liquid biopsy” for monitoring 
of NSCLC patients and confirmed NOTCH1 as a potential therapeutic target to block lung cancer 
dissemination.
Cancer is a major public health concern in developed countries with lung cancer as the leading cause responsible 
for 19.4% of cancer deaths worldwide1. Of those, Non-Small Cell Lung Cancer (NSCLC) accounts for 85% of 
all cases and encompasses high genetic and histological heterogeneity2. Clinically, treatment alternatives attains 
a 54% 5-year survival when disease is localized but only 4% when disease is diagnosed once metastasis has 
occurred3. In this scenario, and despite of the increase in survival during the last decade due to the incorporation 
of new drugs and better treatment selection4, NSCLC remains an incurable disease in the metastatic setting. Since 
more than 58% of patients present locally advanced or metastatic disease at the moment of diagnosis3, strategies 
to understand and target the metastatic process constitute a priority in NSCLC.
Circulating Tumour Cells (CTCs) represent a principal component of the step-wise process of metastasis in 
which tumour cells escape from the primary tumour, invade the vascular and lymphatic systems, and incorporate 
into the circulation. Some of these cells are able to survive in the absence of physical substrate until, eventually, 
reattach at a distant organ and colonize it. Only recently, expanded CTCs ex vivo from early stage lung cancer 
have been observed to carry the same genetic alterations as primary tumors5; and when transplanted CTCs have 
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been able to generate new tumour masses in mouse model while maintaining the genetic and biological charac-
teristics of the origin tumor6. Moreover, CTCs enumeration has proven to correlate with poor prognosis in several 
cancers including NSCLC7,8.
To this regard, CTC evaluation allows readily “liquid biopsy” meanwhile access to surgical and/or biopsy 
specimens is often insufficient and fails to reflect tumour dynamics, heterogeneity or even drug sensitivity. 
Therefore, CTCs represent a powerful tool for disease management in agreement with the importance of devel-
oping non-invasive biomarkers to monitor tumour dynamics at real-time9.
In this work we present a methodology for the recovery of EpCAM positive CTCs from advanced NSCLC 
patients, followed by whole genome amplification and gene expression array analysis to characterize this meta-
static population. Although EpCAM expression is frequently lost during cancer progression in NSCLC, EpCAM 
expression in CTCs correlates with poorer outcome in previous studies8, while EpCAM negative CTCs failed to 
prove prognostic value in lung cancer10. As from these data we were able to describe a panel of genes specifically 
expressed in CTCs from advanced NSCLC patients, and to improve our understanding on the biology of the sub-
population of CTCs in NSCLC. Moreover, we characterized NOTCH1 as main signalling pathway that illustrate 
their fate, and identified potential biomarkers with clinical significance.
Results
Immunoisolation and molecular profiling of CTC from advanced NSCLC patients. The presence 
of CTCs in advanced NSCLC was assessed by combining EpCAM-based immunoisolation and RT-qPCR analysis 
of GAPDH in a series of 42 advanced NSCLC patients (Supplementary Table S1) and 16 healthy donors. GAPDH 
has been stated as a reference marker of global cellularity when normalized to the recovery of CD45 as a marker 
of the non-specific isolated lymphocytes11, herein demonstrating the presence of an additional population in 
advanced NSCLC patients (p < 0.001; Fig. 1a). Also consistently, CD45 expression showed no significant dif-
ferences when evaluated for both groups revealing same unspecific recovery in patients and controls (data not 
shown) and no power was observed for early progression in the cohort of patients (AUROC: 0.522) while GAPDH 
presented an AUROC 0.747 (Fig. 1b). Additionally, when CD45 gene expression was assessed in the remaining 
cellular fraction upon CTC immunoisolation no significant differences were found between patients and con-
trols, revealing that CTC specific gene expression is not associated with differential expression in the non-CTC 
population11.
Molecular profiling of CTCs in advanced NSCLC was approached by subtracting the background of unspecific 
immunoisolation from healthy donors (n = 4) to the global gene expression profile of EpCAM-based immunoi-
solated CTCs from patients (n = 10; Supplementary Table S2), as described by Barbazan et al.11. Experimental 
workflow for CTC isolation and enrichment, RNA extraction, whole transcriptome amplification and array 
Figure 1. CTC detection and gene expression profiling. (a) GADPH expression in CTC immunoisolated 
from advanced NSCLC patient (n = 42) and control (n = 16) groups. (b) AUROC curve for GAPDH and CD45 
detection for RT-qPCR. Unspecific-isolated lymphocytes do not predict early progression (< 4 months).  
(c) Principal component dot plot for differential distribution of NSCLC patients and healthy donors based on 
gene expression microarray. NSCLC patients are grouped constituting a particular population. (d) Schematic 
workflow for CTC gene expression profiling.
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hybridization is depicted in Fig. 1d. Total RNA from CTCs was amplified, complementary DNA was hybridized 
onto Agilent gene expression microarray, and raw data was pre-processed as described in Material and Methods, 
resulting in 2,392 spots (7.01%) that accomplished the quality criteria. Average signal was 60,889 units being 
76,597 and 16,979 units the average signal for patient and control groups respectively. Upon normalization 1,810 
probes with expression greater than 211 in at least 8 patients and 2 controls were considered for any further 
analysis. Assuming Delta parameter to 2.46 for median False Discovery Rate (FDR) = 0 rendered 853 differen-
tiated probes; being considered only the 305 probes with log2 ratio greater than 1.5 (Supplementary Table S3). 
In addition, 8 probes uniquely detected in patients’ samples, with a raw signal meeting the quality criteria, were 
included into subsequent analysis (Supplementary Table S4). Principal Component Analysis (PCA) revealed 
effective discrimination between patients and control samples, NSCLC patients being defined by their pathologic 
status (Fig. 1c).
Biology of CTC isolated from advanced NSCLC patients. Bioinformatic analysis with Ingenuity 
Pathway Analysis (IPA) software was performed to interpret the biology of NSCLC CTCs. Consistently with an 
actively disseminating subpopulation of tumour cells, the main molecular and cellular functions represented by 
the set of CTC-specific genes were related to cellular movement, cell death and survival and cellular development, 
cellular growth and proliferation, mainly orchestrated by PI3K/AKT, ERK1/2 and NF-kB pathways. GeneCodis3 
ontology analysis also highlighted cell adhesion, developmental functions, extracellular matrix organization 
and an active transduction and transport activity (data not shown). Interestingly, NOTCH1 was identified as an 
important actor orchestrating this functional network (Fig. 2a and b). The biological and functional relevance 
of NOTCH1 within this metastatic population was further confirmed by RT-qPCR (Fig. 2c) in the series of 42 
NSCLC patients (Supplementary Table S1). In addition, we assessed the expression of HES1, a downstream target 
gene of NOTCH1, whose expression was found to be significantly increased in patients (p = 0.041; Fig. 2d), in 
correlation with that of NOTCH1 (Fig. 2e). Moreover, we further assessed the functional relevance of Notch1 in 
the subpopulation of CTC in NSCLC by studying the impact of Notch1 pathway inhibition on clonogenic assay, 
as an indirect measure of the metastatic potential of CTC. As shown in Fig. 2f, the γ -secretase inhibitor DAPT 
significantly reduced the ability of A549 cells to grow in the absence of substrate at different concentrations 
in vitro (p = 0.031).
We finally screened the expression levels of LGALS3 (Galectin-3), ITGB3 (Integrin beta-3) and PTP4A3 
(Protein tyrosine phosphatase type IVA 3), associated with the identified NOTCH1 network, in CTC immunoiso-
lated from NSCLC patients. RT-qPCR evaluation showed a significant increased expression of the selected three 
Figure 2. CTC expression profile analysis and NOTCH1 validation. (a) Cellular functions and biological 
networks by IPA for CTC from advanced NSCLC patients. (b) Interaction network for cell movement, cell death 
and survival, cell development and cell growth and proliferation according to CTC expression profile. NOTCH1 
is identified as a main actor orchestrating the network. (c) Validation of specific NOTCH1 gene expression 
in CTC from advanced NSCLC patients (n = 42) as compared to controls (n = 16). (d) HES1 gene expression 
is significantly increased in NSCLC patients compared to controls. (e) NOTCH1 correlates with his effector 
protein HES1 in NSCLC CTCs. (f) Clonogenic assay for A549 adenocarcinoma cells treated with the γ -secretase 
inhibitor DAPT (n = 6).
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candidate genes in the series of CTCs immunoisolated from patients with advanced NSCLC when compared to 
healthy donors (p < 0.05; Supplementary Figure S1). All these results confirmed the relevance of NOTCH1 in 
NSCLC dissemination and validated the bioinformatics analysis and biological information of the gene expres-
sion profiling of EpCAM+ CTCs immunoisolated from advanced NSCLC patients.
Prognostic significance of Notch1 network in CTCs from NSCLC. CTC gene expression profiling 
from advanced NSCLC patients also provided with diagnostic and prognostic markers with potential clini-
cal impact in patient management. Univariate Cox regression analysis showed prognostic utility for NOTCH1 
(p = 0.034), PTP4A3 (p = 0.003), LGALS3 (p = 0.044) and ITGB3 (p = 0.046) to predict Progression-Free 
Survival, and that for ITGB3 (p = 0.006) for Overall Survival. The poor prognosis groups were defined within the 
restrictive 33% of patients with the highest RT-qPCR signal for each biomarker (Supplementary Table S5, upper 
panel). Moreover, GAPDH proved clinical value to predict PFS (p < 0.001) and OS (p < 0.001) as expected for 
an indirect evaluator of the CTC burden (Supplementary Table S5, upper panel). Additionally, the presence of 
bone metastasis was identified as the only clinical parameter with prognostic significance in series of 42 advanced 
NSCLC patients (Supplementary Table S5, lower panel).
Kaplan-Meier analysis confirmed the prognostic value of NOTCH1, PTP4A3, LGALS3, ITGB3, and GAPDH 
biomarkers for PFS (Fig. 3), and that for GAPDH and ITGB3 for OS (Supplementary Figure S2). We further gen-
erated a logistic model with the panel of CTC-biomarkers in order to improve their diagnostic and prognostic 
value. For this, linear regression with a 67% good prognosis versus 33% poor prognosis cut-off for each biomarker 
as previously defined, demonstrated the best performance with an AUROC value of 0.772 for the combination 
Figure 3. Kaplan-Meier curves of validated biomarkers for Progression-Free Survival (PFS). Statistical 
significance determined by log rank test (p < 0.05).
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of GAPDH, NOTCH1 and PTP4A3 in early progression (Fig. 4a). Accordingly, the prognostic value of the panel 
of CTC-biomarkers improved for PFS and OS when defined as a cumulative variable for the markers included in 
the logistic model (Fig. 4b,c).
Finally, multivariate analysis including the panel of five CTC-biomarkers in combination with the presence 
of bone metastasis resulted in GAPDH, NOTCH1 and PTP4A3 as independent predictors of PFS (Table 1, upper 
panel); GAPDH and ITGB3 showed predictive value for OS (Table 1, upper panel). When referred to the cumu-
lative variable of the logistic model CTC-biomarker panel, predictive value was achieved for PFS and OS, as well 
as bone metastasis (Table 1, lower panel).
Discussion
Research on circulating tumour cells (CTCs) has rapidly increased in the last years in response to the clinical 
need of new alternative tools for the management of patients candidate for personalized therapeutic strategies12. 
Traditionally, efforts have been devoted to understand the mechanisms underlying cancer progression mainly 
focused on primary and metastatic carcinomas; but little is known about the “fluid phase” of cancer as the 
relevant actor of tumour dissemination and lethality13. This is particularly relevant in NSCLC, where most 
cases result inoperable and biopsies are rarely obtainable. The analysis and characterization of CTCs in NSCLC 
patients represent a particularly attractive strategy for real-time patient monitoring to support treatment 
decisions14,15.
CTCs exist in extreme rarity in blood; therefore their analysis requires highly sensitive methods. In the last 
decade a number of technologies, not only restricted to immunoisolation, have become available16. Most of the 
commonly used strategies for CTC detection showed promising results in NSCLC, although the amount of data 
available is limited compared to other tumour types17,18. For instance, studies with the FDA-approved CellSearch 
system demonstrated utility for CTC detection with high levels of CTCs at baseline correlating with poor survival 
rates19,20; although heterogeneity in EpCAM expression could limit its applicability in NSCLC patients21. To this 
regard, we must also consider that EpCAM is frequently overexpressed in NSCLC, suggesting an implication 
of EpCAM in carcinogenesis22. In addition, EpCAM positivity was confirmed in our series of samples showing 
strong immunostaining in well-differentiated tumour areas while positivity was moderate in poorly differenti-
ated tumour areas (Supplementary Figure S3). In this work, we focus on EpCAM-positive CTC from advanced 
NSCLC patients, and we approached their global gene expression profiling to better understand their biology and 
to identify and validate CTC-biomarkers with clinical utility in NSCLC.
Figure 4. Prognosis and diagnosis value for the accumulation of biomarkers and logistic model. (a) Linear 
regression model for GAPDH + NOTCH1 + PTP4A3 biomarkers. (b and c) Kaplan-Meier analysis grouping 
patients according to the marrkers included in the regression model for (b) PFS and (c) OS.
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Previous studies on CTC gene expression in NSCLC approached PCR-based technologies analysing subsets 
of genes from CTC enriched samples23,24. We combined CTC immunoisolation, whole genome amplification and 
gene-expression profiling. The specific NSCLC-derived CTCs expression profile is mainly associated with cellular 
movement, cell adhesion and differentiation, and cell-to-cell signalling linked to PI3K/AKT, ERK1/2 and NF-kB 
pathways, previously associated with lung cancer and metastasis25,26; and NOTCH1 playing an important role on 
the whole functional network. Of note, among genes related to cell adhesion we could find tenascin R (TNR) or 
mucin 4 (MUC4), previously associated with lung cancer aggressiveness and dissemination27,28.
Notch signalling is emerging as a valuable molecular pathway for targeting therapies in NSCLC. Clinical 
studies indicate that 30% of NSCLC cases have increased Notch1 signaling29 and this activity seems to be crit-
ical for driving cancer cell migration and metastasis due to repression of cell adhesion molecules, resulting in 
loss of cell-to-cell adhesion, protection against hypoxic conditions and promotion of a stem-like signature30. 
Recent studies have demonstrated that Notch signalling plays an important role in lung cancer initiation via 
crosstalk with transcription factors enhancing epithelial-to-mesenchymal transition (EMT)31. Further, dys-
regulation of Notch signalling as a common feature of NSCLC correlating with poor prognosis has been asso-
ciated with TGF-β and EMT32. Related to this, Notch1 related EMT promotion has been associated with an 
increased EpCAM expression33. Of note, Notch signalling inhibition resulting in a non-significant decreased 
EpCAM expression (Supplementary Figure S3), did not altered the efficiency of EpCAM-based immunoisolation 
of CTC (Supplementary Figure S3). These results indicate that EpCAM-based immunoisolation is effective to 
purify CTC from NSCLC patients, the excess of antibody coupled beads are in excess being able to balance the 
variations in EpCAM expression due to Notch1-related EMT or the presence of poorly differentiated tumour 
cells (Supplementary Figure S3). Similarly, no differences in Notch1 were found between CTC-EpCAM pos-
itive immunoisolated from adenocarcinoma or squamous cell carcinoma origins (data not shown), although 
specific studies should be performed to address the impact of histology or mutational profiles associated with 
smoking34. Also accordingly, HES1 downstream target of NOTCH1, strongly correlated in the CTCs immunoiso-
lated from advanced NSCLC patients, further suggesting the functional involvement of Notch pathway and the 
potential therapeutic value of Notch pathway-directed drugs such as γ -secretase inhibitors or ADAM inhibitors 
in advanced NSCLC35,36.
In addition to NOTCH1, with demonstrated prognostic value in NSCLC37, validated genes involved in the 
identified CTC-network have also been described during NSCLC progression. The expression of the growth/
adhesion-regulatory lectin galectin-3 in stage II NSCLC is indicative of a poor prognosis38,39, playing a role in 
cell motility, invasion, and metastasis40. Similarly, PTP4A3 expression in NSCLC has been described upregulated 
in correlation with advanced clinical stage and distant metastasis linked to microvascular and lymphatic vessel 
formation41. Finally, ITGB3 has been recently described as mediator of NSCLC promotion in the context of K-ras 
addiction42, and whose inhibition by miR-9843 or miR let-7c44 prevented proliferation, migration and invasion 
in NSCLC.
The promising results obtained with the panel of CTC-biomarkers in NSCLC both for detection of metastatic 
disease and classification into favourable and unfavourable outcome guarantee further analysis in a large multi-




HR (95% CI) p value HR (95% CI) p value
GAPDH
 GAPDH (poor vs. good prognosis) 5.67 (2.1–15.6) 0.001 10.29 (3.4–30.7) <0.001
 Bone metastasis (Y/N) 1.16 (0.5–2.7) 0.727 0.74 (0.3–1.8) 0.503
NOTCH1
 NOTCH1 (poor vs. good prognosis) 2.20 (1.1–4.4) 0.027 1.22 (0.6–2.5) 0.582
 Bone metastasis (Y/N) 2.48 (1.2–5.0) 0.011 1.86 (0.9–3.7) 0.087
PTP4A3
 PTP4A3 (poor vs. good prognosis) 3.17 (1.5–6.7) 0.002 1.57 (0.8–3.2) 0.222
 Bone metastasis (Y/N) 2.45 (1.2–4.9) 0.012 1.92 (0.9–3.9) 0.073
LGALS3
 LGALS3 (poor vs. good prognosis) 1.93 (0.9–3.9) 0.067 1.59 (0.8–3.2) 0.204
 Bone metastasis (Y/N) 2.29 (1.1–4.6) 0.021 1.81 (0.9–3.7) 0.101
ITGB3
 ITGB3 (poor vs. good prognosis) 1.72 (0.8–3.5) 0.134 2.72 (1.3–5.6) 0.007
 Bone metastasis (Y/N) 2.12 (1.0–4.3) 0.040 1.59 (0.8–3.3) 0.211
CTC-biomarker panel
 1–3 biomarkers (poor vs. good prognosis) 3.06 (1.5–6.3) 0.002 2.33 (1.1–4.8) 0.022
 Bone metastasis (Y/N) 2.22 (1.1–4.5) 0.028 1.91 (0.9–3.9) 0.077
Table 1.  Multivariate Cox regression analysis for CTC markers and clinicopathological parameters 
individually and in combination. HR: hazard ratio; CI: confidence interval.
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In conclusion, we demonstrated that the combination of CTC immunoisolation and gene expression analyses 
represents an adequate strategy to: a) identify highly specific and sensitive CTC biomarkers with independent 
diagnosis and prognosis value and potential applicability in the management of advanced NSCLC patients; b) 
reveals NOTCH1 as a conducting factor in the biology of EpCAM positive CTCs and a potential therapeutic 
target to impair metastasis dissemination in NSCLC.
Material and Methods
Patient selection. Participants included in the study were diagnosed with advanced stage (unresectable 
stage III or IV) NSCLC on the basis of the International Association for the Study of Lung Cancer (IASLC)/ 
American Thoracic Society (ATS)/European Respiratory Society (ERS) classification criteria. Blood samples were 
collected before the initiation of chemotherapy, in accordance to the guidelines and protocols approved by the 
Institutional Ethical Committee (Galician Clinical Research Ethics Committee, SERGAS; code 2008/277), and 
signed informed consent was obtained from all participants. Candidates who had received chemotherapy previ-
ously to the study were not included.
CTCs evaluation cohort included 42 NSCLC patients with distant metastasis diagnosed in 36 cases 
(Supplementary Table S1). Microarray gene-expression analysis was conducted in an independent set of patients 
and healthy age-matched donors. Distant metastasis was present in 8 out of 10 patients at the moment of recruit-
ment (Supplementary Table S2).
CTC immunoisolation, profiling and Significance Analysis Microarray. CTC isolation was 
performed from 7.5 ml of peripheral blood from advanced NSCLC patients or healthy donors using the 
EpCAM-based CELLectionTM Epithelial Enrich Dynabeads® kit (Invitrogen, Dynal; Oslo, Norway) according 
to manufacturers’ instructions. Isolated CTCs were resuspended in RNA later® (Ambion; Foster City, CA, USA) 
and preserved at − 80°C until use.
Total RNA extraction, Complete Whole Transcriptome Amplification (WTA2, Sigma Aldrich) and gene 
expression array was performed as described by Barbazan et al.11. Briefly, total RNA was extracted with the 
QIAmp viral RNA mini kit (Qiagen, Valencia, CA, USA) specifically designed for very low cellularity samples. 
Subsequent pure RNA was then subjected to Complete Whole Transcriptome Amplification PCR for 20 cycles 
using the maximum amount of RNA; Cy3 labelling and hybridization onto Agilent 4 × 44 k gene expression 
arrays. Upon hybridization, signal was captured and submitted to Significance Analysis for Microarray to identify 
differentially expressed genes (Supplementary Material and Methods S1).
Ingenuity Pathway Analysis (IPA) and Gene Ontology analysis. Gene set characterizing CTC pop-
ulation was analysed with IPA software for representative biological pathways and functions in our data set. 204 
probes were identified as annotated genes (66.6%). Fisher’s exact test was applied to calculate p value of biological 
related functions.
Additionally, CTC specific gene signature was submitted to gene ontology analysis using GeneCodis3 open 
access software45. Singular enrichment Gene Ontology tool was used to obtain a broad overview of the main 
biological processes involved in the CTC profile; of which 193 probes belonged to annotated genes (61.1%). 
Hypergeometrical test (p < 0.05) and FDR correction were used as stated in the software.
Preamplification and quantitative Real-Time PCR validation. CTCs were isolated from an inde-
pendent set of patients and total RNA was extracted with the QIAmp viral RNA mini kit (Qiagen; Valencia, 
CA, USA) as previously stated. Complementary DNA (cDNA) was obtained using SuperScript III reverse 
transcriptase (Invitrogen; Carlsbad, CA, USA) adding 11 μ l of total RNA per reaction. Because of very low cel-
lularity of the samples, cDNA was subjected to 14x pre-amplification cycles (TaqMan® PreAmp Master Mix 
Kit, Applied Biosystems; Foster City, CA, USA) to increase sensibility and stability. Finally, pre-amplified 1:10 
diluted cDNA was subjected to TaqMan RT-qPCR for candidate genes associated with Notch1 network by IPA 
(Supplementary Table S4). GAPDH, a reference gene previously used for CTC quantification in peripheral blood 
and indirect evidence of cellularity11,46, and HES1 as a downstream gene of NOTCH1 (Supplementary Material 
and Methods S1) were also included. Mean threshold cycle (depicted as 40-Ct) for every candidate gene was 
normalized to CD45, a lymphocyte specific marker that allows the quantification of non-specific isolation and 
that have been previously used to discriminate the population of CTCs from the total of nucleated cells isolated in 
blood11,47,48. Samples were run in duplicate and all plates included negative controls.
Cell culture. The human NSCLC cell line A549 was obtained from the American Type Culture Collection. 
A549 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with 10% FBS (Invitrogen). 
Cells were kept at 37 °C under a humidified atmosphere with 5% CO2. Mycoplasma test was conducted 
routinely.
Soft agar assay and Notch1 inhibition. Soft agar assays were conducted on 96-well plates with a base 
layer of 0.6% low melting point agarose and an upper layer of 0.3% low melting point agarose containing 5 × 103 
cells per well. Upper and lower layer were constituted in 2% FBS DMEM.
Inhibition of Notch1 was approached by the addition of 100 μ l of the γ -secretase inhibitor, DAPT (CAS 
208255-80-5, Santa Cruz Biotechnology, Dallas, TX, USA; IC50: 115 nM), or its vehicle (DMSO) at different con-
centrations in FBS-free DMEM. Proliferation was measured five days later by AlamarBlue® Cell Viability Reagent 
(DAL1025, ThermoFisher). Significance was evaluated by Wilcoxon signed rank test (p < 0.05).
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Statistical validation and clinical database contrast. Validation analysis was performed using 
two-tailed Mann-Whitney U-test. Clinical evaluation of validated markers was approached following the 
REMARK recommendations49. Progression-Free Survival (PFS) and Overall Survival (OS) were analysed using 
Kaplan-Meier analysis and differences were examined by log rank test. Univariate and multivariate analyses were 
performed using Cox regression statistics. Bivariate correlation analysis was routinely carried out according 
Pearson statistic. p < 0.05 values were considered statistically significant.
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